A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs PTG 300 (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Acronyms TRANSCEND
- Sponsors Protagonist Therapeutics
- 10 Jan 2019 Status changed from planning to recruiting.
- 05 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018, according to a Protagonist Therapeutics media release.
- 05 Dec 2018 According to a Protagonist Therapeutics media release, the company intent to commence this global Phase 2 trial by the end of 2018.